184 related articles for article (PubMed ID: 2879902)
1. Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes.
Hall SD; Guengerich FP; Branch RA; Wilkinson GR
J Pharmacol Exp Ther; 1987 Jan; 240(1):216-22. PubMed ID: 2879902
[TBL] [Abstract][Full Text] [Related]
2. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.
Wienkers LC; Wurden CJ; Storch E; Kunze KL; Rettie AE; Trager WF
Drug Metab Dispos; 1996 May; 24(5):610-4. PubMed ID: 8723744
[TBL] [Abstract][Full Text] [Related]
3. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction.
Shimada T; Misono KS; Guengerich FP
J Biol Chem; 1986 Jan; 261(2):909-21. PubMed ID: 3079764
[TBL] [Abstract][Full Text] [Related]
4. Participation of a rat liver cytochrome P-450 induced by pregnenolone 16 alpha-carbonitrile and other compounds in the 4-hydroxylation of mephenytoin.
Shimada T; Guengerich FP
Mol Pharmacol; 1985 Aug; 28(2):215-9. PubMed ID: 4022003
[TBL] [Abstract][Full Text] [Related]
5. Mephenytoin hydroxylase activity in human liver: inhibition by steroids.
Jurima M; Inaba T; Kalow W
Drug Metab Dispos; 1985; 13(6):746-9. PubMed ID: 2867882
[No Abstract] [Full Text] [Related]
6. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
7. Role of CYP2C19 in stereoselective hydroxylation of mephobarbital by human liver microsomes.
Kobayashi K; Kogo M; Tani M; Shimada N; Ishizaki T; Numazawa S; Yoshida T; Yamamoto T; Kuroiwa Y; Chiba K
Drug Metab Dispos; 2001 Jan; 29(1):36-40. PubMed ID: 11124227
[TBL] [Abstract][Full Text] [Related]
8. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Mankowski DC
Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
[TBL] [Abstract][Full Text] [Related]
9. Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4'-hydroxylation.
Yasumori T; Li QH; Yamazoe Y; Ueda M; Tsuzuki T; Kato R
Pharmacogenetics; 1994 Dec; 4(6):323-31. PubMed ID: 7704038
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency.
Meier UT; Meyer UA
Biochemistry; 1987 Dec; 26(25):8466-74. PubMed ID: 3442670
[TBL] [Abstract][Full Text] [Related]
11. Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A).
Yasumori T; Chen L; Nagata K; Yamazoe Y; Kato R
J Pharmacol Exp Ther; 1993 Jan; 264(1):89-94. PubMed ID: 8423554
[TBL] [Abstract][Full Text] [Related]
12. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite.
Bajpai M; Roskos LK; Shen DD; Levy RH
Drug Metab Dispos; 1996 Dec; 24(12):1401-3. PubMed ID: 8971149
[No Abstract] [Full Text] [Related]
13. Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes.
Horsmans Y; Lannes D; Larrey D; Tinel M; Letteron P; Loeper J; Pessayre D
Xenobiotica; 1991 Dec; 21(12):1559-70. PubMed ID: 1785203
[TBL] [Abstract][Full Text] [Related]
14. The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides.
Wright JD; Helsby NA; Ward SA
Br J Clin Pharmacol; 1995 Apr; 39(4):441-4. PubMed ID: 7640152
[TBL] [Abstract][Full Text] [Related]
15. The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation.
Chiba K; Saitoh A; Koyama E; Tani M; Hayashi M; Ishizaki T
Br J Clin Pharmacol; 1994 Mar; 37(3):237-42. PubMed ID: 8198931
[TBL] [Abstract][Full Text] [Related]
16. Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo.
Meier UT; Dayer P; Malè PJ; Kronbach T; Meyer UA
Clin Pharmacol Ther; 1985 Nov; 38(5):488-94. PubMed ID: 4053486
[TBL] [Abstract][Full Text] [Related]
17. Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.
Coller JK; Somogyi AA; Bochner F
Br J Clin Pharmacol; 1999 Aug; 48(2):158-67. PubMed ID: 10417492
[TBL] [Abstract][Full Text] [Related]
18. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation.
Chiba K; Kobayashi K; Manabe K; Tani M; Kamataki T; Ishizaki T
J Pharmacol Exp Ther; 1993 Jul; 266(1):52-9. PubMed ID: 8331574
[TBL] [Abstract][Full Text] [Related]
19. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes.
Relling MV; Evans WE; Fonné-Pfister R; Meyer UA
Cancer Res; 1989 Jan; 49(1):68-71. PubMed ID: 2908853
[TBL] [Abstract][Full Text] [Related]
20. (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19.
Suzuki H; Kneller MB; Haining RL; Trager WF; Rettie AE
Drug Metab Dispos; 2002 Mar; 30(3):235-9. PubMed ID: 11854139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
